2026 年第一次临时股东会资料 株洲千金药业股份有限公司 2026 年第一次临时股东会 会议资料 二○二六年一月十二日 2026 年第一次临时股东会资料 2026 年第一次临时股东会会议议程 一、会议安排 （一）现场会议时间：2026 年 1 月 12 日上午 9:30 网络投票时间：2026 年 1 月 12 日上午 9:15-11:30，下午 1:00-3:00 （二）现场会议地点: 湖南省株洲市天元区株洲大道 801 号千金药业三楼会 议室。 资料目录 | 一、2026 | 年第一次临时股东会会议议程································1 | | --- | --- | | 二、2026 | 年第一次临时股东会会议须知································3 | | 三、议案及内容 | | 1.关于选举许大为先生为公司第十一届董事会董事的议案······ 4 2026 年第一次临时股东会资料 株洲千金药业股份有限公司 （三）会议召开方式：本次临时股东会采取现场投票与网络投票相结合的方式。 （四）参加股东会的方式：公司股东应选择现场投票和网络投票中的 ...

Group 1 - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., will hold its first extraordinary general meeting of shareholders for 2026 on January 12, 2026, at 9:30 AM [1][4][28] - The meeting will be conducted using a combination of on-site and online voting methods, with the online voting system provided by the Shanghai Stock Exchange [2][3] - Shareholders must register to attend the meeting, with specific registration procedures outlined for both corporate and individual shareholders [10][11] Group 2 - The voting for the meeting will take place on January 12, 2026, during designated trading hours, with specific time slots for both online and on-site voting [2][5] - There are no special resolutions or related party transactions requiring abstention from voting at this meeting [5][6] - The company will provide detailed materials regarding the meeting agenda and voting procedures on the Shanghai Stock Exchange website by December 31, 2025 [4][28] Group 3 - The meeting will include the election of directors and independent directors using a cumulative voting system, allowing shareholders to allocate their votes among candidates [18][19] - Shareholders must complete their voting for all proposals before submission, and any excess votes beyond their entitlement will be considered invalid [7][8][6] - The company will cover the costs of food and accommodation for attendees, which will be self-managed by the participants [13]

Core Viewpoint - Qianjin Pharmaceutical announced the approval of several proposals, including the nomination of Mr. Xu Dawei as a candidate for the board of directors at the 15th meeting of the 11th board of directors [2] Group 1 - The board meeting was held on December 19 [2] - The company is in the process of appointing new board members [2]

Group 1 - The company, Qianjin Pharmaceutical (stock code: 600479), announced that it will hold its first extraordinary general meeting of shareholders for 2026 on January 12, 2026 [1]

Group 1 - The company, Qianjin Pharmaceutical, announced that it will hold its first extraordinary general meeting of shareholders for 2026 on January 12, 2026, to review proposals submitted by the 15th meeting of the 11th Board of Directors [1] - For the first half of 2025, the revenue composition of Qianjin Pharmaceutical was as follows: 55.83% from drug manufacturing, 41.72% from drug wholesale and retail, 6.91% from other industries, 1.64% from the production of traditional Chinese medicine materials and decoction pieces, and -6.1% from internal offsets [1] - As of the report date, Qianjin Pharmaceutical has a market capitalization of 5.1 billion yuan [1]

第一条 为进一步规范株洲千金药业股份有限公司（以下简称 "公司"）及其控股子公司对外捐赠行为，加强公司对捐赠事项的管 理，全面、有效地提升和宣传公司品牌及企业形象，维护公司股东、 债权人及员工利益，根据《中华人民共和国公司法》《中华人民共和 国公益事业捐赠法》《上海证券交易所股票上市交易规则》及《株洲 千金药业股份有限公司章程》（以下简称"《公司章程》"），制订 本制度。 株洲千金药业股份有限公司 对外捐赠管理制度 第一章 总则 第二条 本制度适用于公司，控股子公司可参照执行。 第三条 本制度所称"对外捐赠"，是指公司以公司名义在帮助社 会抵抗自然灾害、构建和谐生态环境、救助危困群体、增加社会福利 等公益性社会活动中捐赠公司财产的行为。 第四条 实施对外捐赠坚持自愿、量力而行的原则，捐赠批准程 序以及行为的实施必须符合本制度和有关法律、法规、规章以及《公 司章程》的规定。 第二章 对外捐赠的形式及范围 第五条 公司可以用于对外捐赠的财产包括现金和实物资产（包 括库存商品、固定资产及其他有形资产等）。公司生产经营需用的主 要固定资产、持有的股权和债权、国家特准储备物资、国家财政拨款、 受托代管财产、已设置担保物 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-064 株洲千金药业股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2026年第一次临时股东会 召开的日期时间：2026 年 1 月 12 日 9 点 30 分 召开地点：湖南省株洲市天元区株洲大道 801 号千金药业三楼会议室 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (七) 涉及公开征集股东投票权 (五) 网络投票的系统、 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二〇二五年十二月十九日，株洲千金药业股份有限公司（以下简 称"公司"）第十一届董事会第十五次会议以通讯表决方式召开。本 次会议应表决董事 8 人，实际表决董事 8 人。会议情况符合《公司法》 《公司章程》的有关规定。会议审议并通过以下议案： 株洲千金药业股份有限公司 第十一届董事会第十五次会议决议公告 一、关于提名许大为先生为公司第十一届董事会董事候选人的议案 根据公司控股股东提名，经公司董事会提名委员会审议通过，董 事会同意提名许大为先生为公司第十一届董事会董事候选人。 证券代码：600479 证券简称：千金药业 公告编号：2025-063 四、关于召开株洲千金药业股份有限公司 2026 年第一次临时股东会 的议案 公司定于 2026 年 1 月 12 日在公司会议室召开 2026 年第一次临 时股东会，审议公司第十一届董事会第十五次会议提交的议案。 表决结果：8 票赞成，0 票反对，0 票弃权。 该议案尚需提交公司股东会审议。 二、关于制定《株洲千金药业股份有限公司对外捐赠管 ...

Group 1 - The core point of the article is that Qianjin Pharmaceutical has received approval for the registration certificate of hydrochloride rufinamide tablets from the National Medical Products Administration [1] - Qianjin Pharmaceutical's revenue composition for the first half of 2025 is as follows: 55.83% from drug production, 41.72% from drug wholesale and retail, 6.91% from other industries, 1.64% from traditional Chinese medicine materials and decoction pieces, and -6.1% from internal offsets [1] - As of the report date, Qianjin Pharmaceutical has a market capitalization of 5 billion yuan [1]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]